Several brokerages have updated their recommendations and price targets on shares of Galectin Therapeutics (NASDAQ: GALT) in the last few weeks: 8/19/2023 – Galectin Therapeutics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock. 8/15/2023 – Galectin Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They […]